Am J Psychiatry 157:968-974, June 2000
© 2000 American Psychiatric Association
Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder
Karl Rickels, M.D.,
Mark H. Pollack, M.D.,
David V. Sheehan, M.D., M.B.A., and
J. Thomas Haskins, Ph.D.
ABSTRACT
OBJECTIVE: This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety disorder without concomitant major depressive disorder.METHOD: Adult outpatients with generalized anxiety disorder but not major depressive disorder with total scores of 18 or higher on the Hamilton Rating Scale for Anxiety and scores of 2 or higher on its anxious mood and tension factors were eligible. Patients were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks. Primary efficacy variables were final total and psychic anxiety factor scores on the Hamilton anxiety scale and final severity and global improvement item scores on the Clinical Global Impression (CGI) scale.RESULTS: Of the 377 patients entering the study, 370 were included in a safety analysis and 349 in an efficacy analysis. Adjusted mean scores at 8 weeks (last-observation-carried-forward analysis) were significantly lower for one or more of the venlafaxine XR groups in four of four primary and three of four secondary outcome measures than for the placebo group. These included a change of 1.7 (versus 1.3) from baseline on CGI severity item scores and a final score of 2.2 (versus 2.6) on the CGI global improvement item. All doses of venlafaxine XR were well tolerated.CONCLUSIONS: Venlafaxine XR is an effective and well-tolerated option for the short-term treatment of generalized anxiety disorder in outpatients without major depressive disorder.
This article has been cited by other articles:
|
|
|
|
 
D Nutt, C Allgulander, Y Lecrubier, T Peters, and U Wittchen
Establishing non-inferiority in treatment trials in psychiatry -- guidelines from an Expert Consensus Meeting
J Psychopharmacol,
June 1, 2008;
22(4):
409 - 416.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C Allgulander, D Nutt, M Detke, J Erickson, M Spann, D Walker, S. Ball, and J. Russell
A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder
J Psychopharmacol,
June 1, 2008;
22(4):
417 - 425.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
J Psychopharmacol,
November 1, 2007;
21(8):
864 - 872.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Rynn, M. A. Riddle, P. P. Yeung, and N. R. Kunz
Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials
Am J Psychiatry,
February 1, 2007;
164(2):
290 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al.
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
November 1, 2005;
19(6):
567 - 596.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. Liebowitz, A. J. Gelenberg, and D. Munjack
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Arch Gen Psychiatry,
February 1, 2005;
62(2):
190 - 198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Allgulander, A. A. Dahl, C. Austin, P. L.P. Morris, J. A. Sogaard, R. Fayyad, S. P. Kutcher, and C. M. Clary
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Am J Psychiatry,
September 1, 2004;
161(9):
1642 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Hoge, J. E. Oppenheimer, and N. M. Simon
Generalized Anxiety Disorder
Focus,
July 1, 2004;
2(3):
346 - 359.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rickels, R. Zaninelli, J. McCafferty, K. Bellew, M. Iyengar, and D. Sheehan
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
April 1, 2003;
160(4):
749 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Rynn, L. Siqueland, and K. Rickels
Placebo-Controlled Trial of Sertraline in the Treatment of Children With Generalized Anxiety Disorder
Am J Psychiatry,
December 1, 2001;
158(12):
2008 - 2014.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Millan, A. Gobert, F. Lejeune, A. Newman-Tancredi, J.-M. Rivet, A. Auclair, and J.-L. Peglion
S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine
J. Pharmacol. Exp. Ther.,
August 1, 2001;
298(2):
565 - 580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Scott, A. Davidson, and K. Palmer
Antidepressant drugs in the treatment of anxiety disorders
Advan. Psychiatr. Treat.,
July 1, 2001;
7(4):
275 - 282.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Ment. Health,
November 1, 2000;
3(4):
104 - 104.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
